Regulação e direito · 08/12/19981 min de leitura
National Institute of Diabetes and Digestive and Kidney Diseases; Licensing Opportunity and/or Cooperative Research and Development Agreement (CRADA) Opportunity to Develop a Hepatitis C virus (HCV) Vaccine Based Upon the Synthesis and Purification of Non-infectious HCV-like Particles Containing HCV Structural Proteins
Tradução automática local · Idioma original da fonte
Resumo
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) is seeking licensees and/or capability statements from parties interested in entering into a Cooperative Research and Development Agreement (CRADA) to develop a hepatitis C virus (HCV) vaccine based on in the synthesis, large scale production and purification of non-infectious HCV-like particles containing HCV structural proteins (Baumert, TF et al. 1998, J. Virol. 72:3827-3836). The invention claimed in DHHS Reference No. E-009-97/0, ``Synthesis and Purification of Hepatitis C Virus-Like Particles In Vitro'' (TJ Liang, TF Baumert), field 08 Nov 96, is available for licensing (in accordance with 35 U.S.C. 207 and 37 CFR Part 404) and/or further development under one or more CRADAs in the clinically important applications described below in the Supplementary Information section.